1. American Lung Association, Source: Surveillance, Epidemiology, and End Results Program, Division of Cancer Control and Population Sciences, National Cancer Institute.
  2. Patz EF, Jr., Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 2000;174(3):769-74.
  3. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. Jama 2001;285(7):914-24.
  4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111(6):1710-7.
  5. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111(6):1718-23.
  6. Jadvar H, Parker JA: Clinical PET and PET/CT. Springer-Verlag, London, 2005; pp. 117-136.
  7. Schoder H., PET/CT: A New Imaging Technology In Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1419-37.
  8. Shreve PD. Pitfalls In Oncologic Diagnosis With FDG PET Imaging: Physiologic And Benign Variants. Radiographics. 1999 Jan-Feb;19(1):61-77.
  9. Cohade, C,. Uptake in supraclavicular area fat ("USA-Fat"): Description on 18F-FDG-PET/CT. J. Nuclear Medicine 2003; 44:170-176.
  10. Tatlidil R. Incidental Colonic FDG Uptake: Correlation With Colonoscopic and Histopathologic Findings. Radiology 2002; 224: 783-787.
  11. Osman MM. Clinically Significant Innaccurate Localization Of Lesions With PET/CT: Frequency In 300 Patients. J Nuclear Medicine; 44:240-243.
  12. Cohade C. Initial Experience With Oral Conrast In PET/CT: Phantom And Clinical Studies. J Nuclear Medicine 2003; 44: 412-416
  13. Osman Mm. Resipiratopry Motion Artifacts on PET Emission Images Obtained Using CT Attenuation Correction On PET-CT. Eur J Nucl Med Mol Imaging 2003; 30: 603-606.
  14. Antoch G. Whole Body Positron Emission Tomography-CT Optimized CT Using Oral And IV Contrast Materials, AJR Am J Roentgenol 2002; 179: 1555-1560.
  15. Goerres GW. Positron Emission Tomography and PET-CT Of The Head And Neck: FDG Uptake In Normal Anatomy, In Benign Lesions, And In Changes Resulting From Treatment. AJR Am J Roentgenol 2002; 179: 1337-1342.
  16. Dizendorf E. Cause and Magnitude of the Error Induced by Oral CT Contrast Agents in CT-Based Attenuation Correction of PET Emission Studies. J Nucl Med 2003; 44: 732-738
  17. Hoekstra CJ. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000 Jun;27(6):731-43
  18. Demura Y. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003 Apr;44(4):540-8.
  19. Dosimetry - F-18-Fluorodeoxyglucose, NUREG/CR-6345, page 9, September 18, 1992
  20. Wahl, RL, Buchanan, JW, editors. Principles and Practice of Postiron Emission Tomography. Philadelphia: Lippincott Williams & Wilkins; 2002.
  21. http://www.internaldosimetry.com/freedosestimates/adult/linkedpages/f18FDG.html